Hepatocellular carcinoma: Surgical perspectives beyond the barcelona clinic liver cancer recommendations

Table 1 Results of liver resection in a recently published surgical series (after 2005) in which surgery was performed beyond the beyond barcelona clinic liver cancer recommendations

Ref.	Year	Patients (n)	Mortality/morbidity	5-yr survival
BCLC 0-A HCC with portal hypertension
Capussotti et al[43]	2006	66	6.1%/34.8%	40.80%
Ishizawa et al[51]	2008	136	-/10%	56.00%
Cucchetti et al[44]	2009	79	4.5%/38.5%	56.50%
Ruzzenente et al[46]	2011	29	2.2%/33.7%	57.3%(72.4%)1
Santambrogio et al[45]	2013	63	0.5%/28.6%	48.00%
BCLC A-B multiple HCCs
Ishizawa et al[51]	2008	126	-/15%	58.00%
Ruzzenente et al[33]	2009	30 ( ≤ 3 nodules)	-/-	46.00%
Ho et al[59]	2009	97 ( ≤ 3 nodules)	-/-	40.00%
Huang et al[57]	2010	26 ( ≤ 3 nodules)	0%/27.8%	69.20%
Torzilli et al[25]	2013	54 (> 3 nodules)	-/-	12.00%
Zhong et al[29]	2013	58 (> 3 nodules)	3.1%2/28.0%2	24.00%
BCLC B large HCC
Pawlik et al[64]	2005	300 (≥ 10 cm)	5.0%/-	27.00%
Pandey et al[62]	2007	166 (≥ 10 cm)	3.0%/30.0%	28.60%
Cho et al[63]	2007	61 (> 5 cm)	1.6%/-	52.90%
Ruzzenente et al[33]	2009	46 (> 5 cm)	-/-	29.00%
Yamashita et al[65]	2011	53 (≥ 10 cm)	3.8%/24.5%	35.00%
Zhong et al[29]	2013	199 (> 5 cm)	3.1%2/28.0%2	41.00%
BCLC C HCC with macrovascular invasion
Pawlik et al[32]	2005	102 (PVTT and HVI)	5.9%/-	10.00%
Le Treut et al[84]	2006	26 (PVTT and HVI)	11.5%/38.5%	13.00%
Ruzzenente et al[33]	2009	17 (PVTT and HVI)	-/-	20.00%
Inoue et al[81]	2009	49 (PVTT)	0%/-	39%-41%
Ban et al[82]	2009	45 (PVTT)	0.0%/21.1%-23.1%	22.40%
Chok et al[79]	2013	88 (PVTT)	3.4%/37.1%	11.2%-14.3%
Wang et al[76]	2013	25 (HVI)	0.0%/40.0%	13.50%

¹5-year survival rate after limited liver resection in Child-Pugh A patients;

²Mortality and morbidity rates in BCLC B patients with both multinodular and large HCCs. PVTT: Portal vein tumour thrombosis; HVI: Hepatic veins invasion; BCLC: Barcelona clinic liver cancer; HCC: Hepatocellular carcinoma.